MinervaX
Minervax ApS develops vaccines against Group B streptococcus (GBS) infections
Total raised
€178M
€177,800,000
Funding rounds
5
Investors
16
distinct backers
Active since
2018-12
latest 2023-10
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood22
base rate 30% for Other
- ▼ Overdue vs cohort gap
- ▼ Low backer re-investment
Exit likelihood28
base rate 12% (2+ rounds)
- ▲ 5 rounds raised
- ▲ €100M+ raised
- ▲ 16y since founding
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
5 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-10-11 | Other | €54M | Adjuvant Capital,EQT Life Sciences,Industrifonden,LF Investment,Novo Holdings,OrbiMed+5 more | View deal → |
| 2022-12-16 | Debt | €50M | European Investment Bank | View deal → |
| 2022-12-16 | Other | €22M | Adjuvant Capital,Industrifonden,LF Investment,Pureos Bioventures,Repair Impact Fund,Sanofi Ventures+3 more | View deal → |
| 2020-12-15 | Series B | €47M | — | View deal → |
| 2019-01-01 | Other | €4.4M | Repair Impact Fund,Sunstone Capital | View deal → |
Investors
16Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Oura Health€779MFinland · Healthtech
- Doctolib€734MFrance · E-commerce